Manidipina Generis

Manidipine Dihydrochloride, the active ingredient in Manidipina Generis, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure.

GNH USA supplies Manidipina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Manidipine, a dihydropyridine calcium channel blocker, is used to treat conditions related to elevated vascular resistance. - Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. - Essential hypertension: provides long‑term blood pressure control to reduce cardiovascular strain. - High blood pressure: assists in achieving target blood pressure levels as part of antihypertensive therapy.

Manidipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate head pain. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: light‑headed feeling, especially on standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing Manidipine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Cardiovascular disease: use cautiously in patients with severe aortic stenosis or heart failure. - Liver impairment: dose adjustment may be needed in hepatic dysfunction. - Concomitant diuretics: monitor electrolytes and renal function. - Pregnancy and lactation: avoid use as safety has not been established. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Manidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels, risk of hypotension. - Grapefruit juice: can elevate drug concentration, leading to adverse effects.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause additive blood pressure lowering. - Diuretics: increase risk of electrolyte imbalance and hypotension. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.